Corcept Raises 2026 Revenue Outlook, Forecasts Q2 Profitability Amid FDA Ovarian Cancer Approval

Corcept Therapeutics (NASDAQ:CORT) posted Q1 2026 revenue of $164.9 million, a modest 5% increase over the same period last year, but operating expenses surged to $214.5 million, driving a net loss of $31.8 million, or $0.30 per diluted share.

The company’s cash and investments fell to $515.4 million at the end of March, down $17 million from the December balance sheet, yet the balance remains ample to fund its expanding clinical agenda.

Guidance Upgrade

Management raised its 2026 revenue target to a $950‑$1,050 million range, up from the prior $850‑$950 million outlook. The boost reflects accelerating sales of Korlym and its authorized generic in the Cushing’s syndrome franchise, as well as anticipated commercial uptake of Lifyorli (relacorilant) in combination with nab‑paclitaxel. Executives said they are confident the drug will capture a meaningful share of the platinum‑resistant ovarian cancer market after its accelerated FDA approval in March—three months ahead of the PDUFA deadline—and its inclusion as a preferred regimen in the NCCN guidelines.

Pipeline Momentum

Corcept highlighted a slate of data releases that could broaden its revenue base: - ROSELLA Phase 3 met both primary endpoints (PFS and OS) and was published in The Lancet. - GRACE Phase 3 results appeared in The Lancet Diabetes & Endocrinology. - MOMENTUM data at ACC showed a 27.3% prevalence of hypercortisolism in resistant hypertension, supporting a potential new indication. - Late‑stage studies such as BELLA Part A, STELLA, and TRIDENT remain on track, while early‑stage combos (nenocorilant + nivolumab; relacorilant + enzalutamide) continue enrollment.

The company expects the Q2 2026 quarter to swing back into profitability, driven primarily by Lifyorli launch ramp‑up and continued growth in the Cushing’s business, which recently transitioned to a new pharmacy vendor to meet record patient starts.

Market Reaction

Shares edged lower, down 0.15% to $46.52, as investors digested the mixed earnings versus the upbeat guidance. The stock remains near the lower third of its 52‑week range, with a relatively high RSI of 72 indicating overbought pressure.

Legal Headwinds

Corcept disclosed ongoing securities‑fraud class‑action litigation, with lead‑plaintiff filing deadlines of April 21. While the filing does not alter the financial outlook, it adds a layer of risk that investors will monitor.

The company will field questions on the earnings call scheduled for 5:00 p.m. ET on April 30, with a webcast available thereafter.